Cti Biopharma Corp. Announced The Us Food And Drug Administration (Fda) Has Approved Vonjo (Pacritinib) For The Treatment Of Adults With Intermediate Or High-Risk Primary Or Secondary (Post-Polycythemia Vera Or Post-Essential Thrombocythemia) Myelofibrosis With A Platelet Count Below 50
